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Pouchitis: a tridimensional view 
Emanuele Sinagra1,2,3, Dario Raimondo1, Giancarlo Pompei4,Gaetano Cristian Morreale5, 
Francesca Rossi1, Salvatore Marasà7, Marco Calvaruso8, Giuseppe Mastrocinque9, Stefano 
Mandalà10, Guido Martorana10, Pier Enrico Marchesa10, Aroldo Gabriele Rizzo4, Georgios 
Amvrosiadis 5, Francesco Cappello3,6; Francesco Carini 6, Giovanni Tomasello3,6
1Gastroenterology & Endoscopy Unit, Fondazione Istituto San Raffaele - G. Giglio, Contrada Pietrapollastra Pisciotto 90015, Ce-
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Contrada Pietrapollastra Pisciotto 90015, Cefalù, Italy; 5Gastroenterology & Hepatology Unit, DIBIMIS, AOUP Paolo Giacco-
ne, University of Palermo, Piazza delle Cliniche 2, 90100, Palermo,Italy; 6Department of Experimental Biomedicine and Clinical 
Neuroscience, Section of Human Anatomy, (BIONEC), University of Palermo, Italy; 7Centro Diagnostico Marasà, Palermo, Italy; 
8Pathology Unit, Ospedali Riuniti “Villa Sofia – Cervello, University of Palermo, via trabucco 180, 90136 Palermo, Italy; 9Urology 
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Summary. The preferred surgical treatment of ulcerative colitis (UC) and familial adenomatous polyposis 
(FAP) is represented by proctocolectomy with ileal pouch-anal anastomosis (IPAA). However, patients with 
UC who have undergone IPAA are prone to develop several complications, which include surgery related/
mechanical complications; inflammatory or infectious disorders; functional disorders; dysplasia or neoplasia; 
and systemic or metabolic disorders. Pouchitis, which is defined as the acute and/or chronic inflammation of 
the ileal reservoir, represents the most common long-term adverse sequela after IPAA. Gut microbiota play 
a pivotal role in the initiation and disease progression of pouchitis. Pouchitis can be classified according to 
the activity of the disease, the duration of the symptoms, the pattern of the disease or response to antibiotic 
therapy. Patients with IPAA for UC tend to experience a variety of symptoms, ranging from mild pelvic or 
perianal discomfort to a debilitating complex of symptoms that may eventually lead to pouch excision thereby 
necessitating the construction of a permanent ileostomy. To date, the etiology, the diagnosis and the medical 
management of pouchitis represent a clinical challenge. In fact pouchitis range from a disease with an acute 
antibiotic-responsive presentation to a chronic antibiotic-refractory form, with subsequent different disease 
mechanisms and clinical course. A tridimensional and multidisciplinar approach, including endoscopy, histol-
ogy, and laboratory testing is widely helpful to identify the different phenotypes of the disease and to manage 
correctly its treatment.
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Epidemiology
The preferred surgical treatment of ulcerative coli-
tis (UC) and familial adenomatous polyposis (FAP) is 
represented by proctocolectomy with ileal pouch-anal 
anastomosis (IPAA), which could be considered a bet-
ter alternative to proctocolectomy with permanent 
ileostomy, since it preserves intestinal continuity and 
sphincter function and removes the entire colorectal 
mucosa. The IPAA consists of total abdominal colec-
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tomy, stripping of the rectal mucosa with preservation 
of the anal sphincter, and the construction of an ileal 
pouch that is anastomosed to the anus (1).
In the case of UC, up to 30% of affected patients 
will require surgical management of their disease be-
cause of medically intractable disease, fulminant course, 
dysplasia or cancer and even due to patient preference 
not to take medication on an indefinite timeline (1).
However, patients with UC who have undergone 
IPAA are prone to develop several complications, 
which include surgery related/mechanical complica-
tions; inflammatory or infectious disorders; functional 
disorders; dysplasia or neoplasia; and systemic or met-
abolic disorders (2).
Pouchitis, which is defined as the acute and/or 
chronic inflammation of the ileal reservoir, represents 
the most common long-term adverse sequela after 
IPAA (3). 
According to some series approximately 50% of 
patients can be expected to experience at least one
episode of pouchitis. In a study of complications 
and long-term outcomes in 1310 patients who under-
went IPAA for chronic UC, 559 patients had at least 
one episode of pouchitis (4). The cumulative risk of 
having at least one episode was 18% at 1 year after 
surgery and 48% at 10 years. Approximately 394 of the 
559 patients who had at least one attack of pouchitis 
had a second episode. The cumulative probability of 
having a second episode after an initial attack within 2 
years of IPAA was 64%.
Several studies show that most cases of pouchitis 
occur within the first few years after IPAA (5) while 
others, conversely, report that risk could continue to 
increase during further follow-up (6) Interestingly, 
pouchitis rarely occurs in patients who have IPAA for 
familial adenomatous polyposis (FAP) (7). 
Several risk factors for pouchitis have been report-
ed, although they have not been demonstrated consis-
tently. Extensive or severe UC (8) backwash ileitis (9) 
extraintestinal manifestations of UC (10,11) precolecto-
my thrombocytosis (12,13) pANCA positivity (14,15) 
nonsmoking status, and nonsteroidal antiinflammatory 
drug (NSAID) use (16-18) have all been reported as 
risk factors for the development of pouchitis.
However, there is little agreement in the litera-
ture as to which factors definitely increase a patient’s 
risk for pouchitis. This discrepancy could be due to 
duration and intensity of follow up after IPAA (19); 
diagnostic criteria of pouchitis used; stratification of 
pouchitis — acute versus chronic pouchitis or a com-
bination of both (20); inclusion or exclusion of CD 
of the pouch (18) or cuffitis (21); and the number of 
patients studied (22).
Classification
Pouchitis can be classified according to the activ-
ity of the disease, the duration of the symptoms, the 
pattern of the disease or response to antibiotic therapy. 
With regard to disease activity, pouchitis can be clas-
sified as in remission or mildly, moderately, or severely 
active, based on symptoms. With regard to duration, 
pouchitis can be classified as acute (<4 weeks) or 
chronic (more than 4 weeks). On the other hand, dis-
ease pattern can be classified as infrequent (1–2 acute 
episodes), relapsing ( more than 3 acute episodes) or 
continuous. Relapsing pouchitis is also considered a 
form of chronic pouchitis. Finally, with regard to re-
sponse to standard antibiotic therapy, pouchitis can be 
classified as responsive, dependent or refractory (23).
Clinical features
Patients with IPAA for UC tend to experience a 
variety of symptoms, ranging from mild pelvic or peri-
anal discomfort to a debilitating complex of symptoms 
that may eventually lead to pouch excision thereby ne-
cessitating the construction of a permanent ileostomy. 
Clinicians typically base their suspicion of pouchitis 
on a constellation of clinical symptoms such as: an 
increase in stool frequency, tenesmus, change in stool 
consistency, abdominal cramps and rectal bleeding. 
Treatment is often prescribed based on these clinical 
symptoms alone.
However, diagnosis of pouchitis based on symp-
toms alone has been shown to be non-specific due to 
the fact that symptoms can originate from a myriad 
of aetiologies, not necessarily inflammatory in nature.
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Etiology
Gut microbiota play a pivotal role in the initiation 
and disease progression of pouchitis (2).
The contribution of gut microbiota to the patho-
genesis of pouchitis is multifaceted: firstly, through the 
dysbiosis (24-27) and therefore, through the emer-
gence of pathogenic bacteria, fungi, or viruses (28). 
The role of dysbiosis in the pathogenesis of pouchitis 
is not yet fully clear, as it is in the field of inflammatory 
bowel disease (29) 
The construction of the ileal reservoir provoke an 
altered bowel anatomy that can lead to fecal stasis and 
colonic metaplasia in the pouch body from the original 
ileal mucosa, thus creating an environment favourable 
to the development of inflammation (30).
Pathogen-associated pouchitis can occur in a sub-
set of patients. C difficile infection (CDI) is common in 
symptomatic patients with IPAA. Other pathogens have 
been reported to be associated with episodes of active 
pouchitis, including C perfringens, Campylobacter species, 
group D streptococci (Enterococcus species), haemolytic 
strains of E coli, and cytomegalovirus (CMV) infection 
(31-35). These pathogenic microbes detected in pouchi-
tis patients with systemic symptoms may contribute to 
disease episodes or be responsible for a refractory course 
to conventional antibiotic therapy (2). Furthermore, such 
bacterial species may exert different impacts on innate 
and adaptive mucosal immune function. 
Table 1 shows the mechanisms of involvement of 
innate and adaptive immunity in the pathogenesis of 
pouchitis.
Work-up
At the initial occurrence of symptoms that might 
suggest a pouchitis, infectious aetiologies should be 
firstly ruled out, through stool for culture, Clostridium 
difficile toxin assay and cytomegalovirus tissutal poly-
merase chain reaction.
Once infectious aetiologies and other possible 
contributors have been excluded, pouch endoscopy 
should be performed. With regard to the opportu-
nity to administer a trial of antibiotics as being both 
therapeutic and diagnostic of ‘pouchitis’, this practice 
should be avoided, because patients with pouch symp-
toms may respond quite rapidly to the administration 
of antibiotics without having evidence of the endo-
scopic or histological inflammation that is required to 
make a diagnosis of pouchitis.
On endoscopy, it is important: (a) to examine the 
pouch, the pre-pouch ileum and the rectal cuff;(b) the 
bioptic sampling of the pre-pouchileum and the rec-
tal cuff; (c) the evaluation of the endoscopic features 
of pouchitis, that may range from anywhere between 
minimal changes, including erythema, friability and 
mucus exudate to ulcers and bleeding. 
Table 1. Involvement of innate immunity in the pathogenesis of pouchitis
Mechanisms through which innate immunity is involved in 
the pathogenesis of pouchitis
Colonic metaplasia related-dysbiosis, with specific regard to 
production of sulfate-reducing bacteria
Alterations in mucin glycoproteins 
Increased permeability of the gastrointestinal mucosa
Aberrant expression of Toll-like receptors
Altered expression of Paneth-cell–specific human defensin-5 
Mechanisms through which adaptive immunity is involved in 
the pathogenesis of pouchitis
Increased proliferation of immature plasma cells 
Increased production of proinflammatory cytokines, such as 
TNF, and proinflammatory neuropeptides
Increased production of cell adhesion molecules
Increased production of platelet-activating factor
Increased production of lipoxygenase products of arachidonic 
acids
Increased production of VEGF
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Two composite scores are used to the diagnostic 
and prognostic assessment of pouchitis. These are the 
pouchitis disease activity index (PDAI) (36) and the 
pouchitis activity score (PAS) (37)
In the first one, an overall score is calculated from 
three separate sixpoint scales including clinical symp-
toms, endoscopic findings and histological changes. 
Furthermore, the PDAI incorporates histological fea-
tures of acute inflammation, and establishes a cut-off 
for differentiation between ‘pouchitis’ (≥7 points) and 
‘no pouchitis’ (<7 points). 
On the other hand, the PAS includes findings 
similar to those of the PDAI but also comprises the 
histological features of chronic inflammation, distin-
guishing three grades of pouch inflammation: mild 
adaptive, moderate pouchitis and severe pouchitis. 
Recently, Elder and coworkers evaluated the en-
doscopic features associated with ileal pouch features 
(38). The authors concluded that distorted appearance 
of “beak” portion of owl’s eyes along with Crohn’s dis-
ease of the pouch or surgery-related complications, 
postoperative use of biologics, and persistent cuffitis 
were the risk factors associated with pouch failure, and 
that the assessment of endoscopic owl’s eye structure 
may provide an additional clue to predict pouch out-
come (38).
Histological assessment will focus on acute in-
flammatory infiltrates, however also dysplastic changes 
Figure 1. Endoscopic view of the pouch inlet in a patient with mild pouchitis.
Figure 2. Another endoscopic view of the pouch inlet in a patient with mild pouchitis.
Figure 3. Endoscopic view of an healthy pre-pouch ileal mucosa.
Figure 4. This edge of colonic mucosa shows the characteristics of an inflammatory infiltrate of mild intensity: reduction of the glan-
dular amount of the epithelium, almost disappearance of the secreting activity and distortion of the residual glandular elements, due 
to the compressive effect of the inflammatory infiltrate. Bar: 200 micra.
Figure 5. A greater enlargement in which we find the same morphological characteristics previously described: reduction of the 
glandular elements and presence of a polymorphous inflammatory infiltrate, consisting of lymphocytes, plasma cells and granulocytes. 
Bar: 200 micra.
Figure 6. This further enlargement underlines the marked amount of granulocytes (settling element for the diagnosis of an inflam-
matory bowel disease), and shows also a certain degree of intraepithelial involvement from the inflammatory elements towards the 
glands. To notice some apoptotic nuclei at the base of the glandular elements. Bar: 200 micra.
Figure 7. Endoscopic view of the pouch inlet in a patient with severe pouchitis
Figure 8. Another endoscopic view of the pouch inlet in a patient with severe pouchitis
Figure 9. Endoscopic view of an inflamed pre-pouch ileal mucosa in a patient with severe pouchitis
Figure 10. In this second case, the intensity of the inflammatory infiltrate can be classified as severe. The inflammatory infiltrate, 
besides colonizing the proper foil giving all those morphological modifications described in Fig. 4, extends him to also involve the 
muscularis mucosae, transmurally. Bar: 200 micra.
Figure 11. In this greater enlargement it can be observed the total disappearance of the glandular amount of the epithelium, entirely 
replaced by the ulcerative inflammation. Bar: 200 micra.
Figure 12. Also in this figure, the eosinophylic component is preponderant. The polymorphous inflammatory infiltrate distorts and 
reduces in dimensions the small residual glands. Bar: 200 micra.
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should be ruled out in the rare case of progression to 
malignant transformation.
Abdominal and pelvic CT scan, pelvic MRI, perineal 
or transanal ultrasound, pouchography or examination 
under anaesthesia are requested in the case of signs of 
inflammation, fistulas, leaks or abscesses.
Medical management
Antibiotics showed widely their effectiveness in 
treating pouchitis (39). Oral metronidazole (at a dose 
of 1 to 2 g daily) (40,41) and oral ciprofloxacin (at a 
dose of 1 g daily) are an effective treatment for pouchi-
tis (42,43). Treatment may be most effective with acute 
episodes, and was found to be less effective in patients 
with a chronic course of the disease. 
Oral metronidazole, in a double-blind cross-over 
randomised trial, was associated with a significant re-
duction in stool frequency by three movements per day 
(versus an increase of one per day with placebo) even 
if absence of changes in the endoscopic or histologic 
grade of inflammation (39).
In another randomized trial consisting of 16 pa-
tients, assigned to either ciprofloxacin 1 g/day or metro-
nidazole 20 mg/kg per day, a response to both drugs was 
showed, but a better improvement and fewer side effects 
(0 versus 33 percent) were found with ciprofloxacin (42)
For this reason, ciprofloxacin at 1 g daily is pri-
marily used as the initial treatment for acute pouchi-
tis, therefore reserving metronidazole for patients in 
which ciprofloxacin fails.
Rifaximin has also been used in pouchitis, even if it 
was not more effective than placebo in a small controlled 
trial (44). However, rifaximin maintenance therapy was 
effective in preventing relapse in 65 percent of patients 
with antibiotic-dependent pouchitis after induction of 
remission with a variety of antibiotics (45).
On the other hand, a combined approaches, in-
cluding ciprofloxacin and rifaximin (46,47) metroni-
dazole and ciprofloxacin (48) and ciprofloxacin and 
tinidazole (49)have also been found to be efficacious 
in the treatment of chronic refractory pouchitis (50).
Interestingly, in a study performed by McLaugh-
lin and coworkers, fecal coliform sensitivity testing was 
showed to be helpful in clarifying the choice of effective 
antibiotics in patients with antibiotic-resistant pouchitis 
(51), allowing to achieve a clinical remission through an 
individualized therapy in 80 percent of patients. 
In the case of antibiotic failure, budesonide may 
be a treatment option. Oral budesonide (9 mg/day for 
eight weeks) was effective in a series of patients with 
acute pouchitis refractory to antibiotics (52).
Budesonide suppositories for four weeks showed 
endoscopic improvement or remission at the end of 
the treatment in all patients with acute pouchitis (53), 
even if with a high degree of early recurrence. In an-
other controlled trial, 26 patients were randomly as-
signed to budesonide enemas (2 mg per 100 mL at 
bedtime) plus placebo tablets or oral metronidazole 
(500 mg twice daily) plus placebo enemas (54). Both 
the treatment were associated with a clinical improve-
ment but adverse effects were more common in pa-
tients receiving metronidazole.
With regards to probiotics, trials about the treat-
ment of mild/moderate pouchitis are few, with small 
numbers of adult patients (55). To date, there is lim-
ited evidence for a role of probiotics as monotherapy 
for mild to moderate pouchitis at the present time, 
as showed by the trials performed by Kuisma, Laake 
and Gionchetti (56,57). On the other hand, two trials 
have studied whether there is an advantage to initi-
ate probiotics immediately following ileal pouch-anal 
anastomosis to evaluate the eventual delay in onset of 
development of pouchitis (58,59).
Furthermore, small controlled trials have also sug-
gested that at least one probiotic preparation (VSL#3™) 
may be effective in prevention of recurrent pouchitis af-
ter antibiotic induction of remission (60-63)
On the basis of the aforementioned data, clinical 
practice guidelines on management of pouchitis (64) 
suggested either VSL#3™ or chronic use of antibiotics 
for those patients with prompt recurrence of pouchitis 
following antibiotic usage or having multiple recur-
rences of pouchitis despite antibiotics, but does not 
suggest probiotics for acute treatment of pouchitis. 
Glucocorticoid and/or mesalamine enemas fol-
lowed by a short course of oral steroids if enemas can-
not be retained can be used as a therapeutic trial (65)
Infliximab was effective long-term (20 months) in 
IPAA patients with refractory luminal inflammation 
and in three of seven patients with pouch fistulas (66). 
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However, risks and benefits need to be considered; and 
this treatment (such also the treatment with 6-mer-
captopurine or azathioprine) is likely reserved for pa-
tients with the most severe symptoms. 
Perspectives and conclusions
On the basis of the aforementioned data, we can 
deduce that microbiota play a pivotal role in the
pathogenesis of pouchitis. Conversely, the inves-
tigation of the role of gut microbiota in the etiopatho-
genesis of pouchitis has been difficult because most of 
gut bacteria are not culturable (67).
In fact molecular microbiology techniques for 
the qualitative and quantitative measurement of mi-
crobiota are expensive and labor-intensive, particularly 
for the identification of the individual responsible bac-
teria.. Therefore, the interpretation of the microbiota 
changes in cross-sectional studies comparing healthy 
and diseased pouches results challenging. 
Due to the dysbiosis, despite intermittent or 
chronic antibiotic therapy or probiotic therapy, an 
abnormal mucosal immune response lead to chronic 
pouchitis or chronic antibiotic-refractory pouchits. 
Furthermore, patients with genetic susceptibility (such 
as those with a NOD2/CARD15 mutation) and/or 
systemic immune-mediated disorders (such as PSC, 
IgG4-associated systemic disorders) result mainly ex-
posed to the development of chronic antibiotic-refrac-
tory pouchits. A molecular classification of pouchitis, 
with a combined assay of immunogenetic, serologic, 
and clinical markers, should be advisable (2).
As a consequence, patients with IPAA should 
be monitored closely. Pouchoscopy is the best way to 
monitor the anatomic status of the pouch, the degree 
of inflammation, and the structural abnormalities. For 
patients with the endoscopic finding of diffuse pouchi-
tis and diffuse enteritis of the afferent limb, immune-
mediated pouchitis/enteritis should be considered. 
For patients with pouch inflammation that is dis-
tributed asymmetrically and has a clear demarcation 
of inflamed and noninflamed parts of the pouch body, 
ischemic pouchitis should be suspected.
When pouchoscopy shows abnormalities such as 
strictures, fistulas, and sinuses, CD of the pouch should 
be suspected, therefore abdominal and pelvic imaging 
or examination under anaesthesia are often requested.
In patients with typical symptoms (increased 
bowel frequency, watery stools, or urgency) antidiar-
rheal agents can be used first. If the symptoms do not 
improve in few days, the patient should be evaluated 
and in some cases treated empirically with antibiotics. 
A prolonged course of dual antibiotic therapy 
may help induce remission in patients with chronic 
antibiotic-refractory pouchits. On the other hand, oral 
or topical mesalamine agents and a topically active 
corticosteroid agent (such as budesonide) are the pre-
ferred first-line drugs for immune-mediated pouchi-
tis/ enteritis. Second-line therapies include immuno-
suppressants (such as 6-mercaptopurine/azathioprine, 
methotrexate, tacrolimus), or anti-TNF agents.
To date, the aetiology, the diagnosis and the med-
ical management of pouchitis represent a clinical chal-
lenge. In fact pouchitis range from a disease with an 
acute antibiotic-responsive presentation to a chronic 
antibiotic-refractory form, with subsequent different 
disease mechanisms and clinical course. A tridimen-
sional and multidisciplinar approach, including endos-
copy, histology, and laboratory testing is widely helpful 
to identify the different phenotypes of the disease and 
to manage correctly its treatment.
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